Peptide Initiative

Peptides · Peptide comparison

Cartalax vs Ventfort

Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression

Vascular peptide bioregulator complex derived from bovine aorta containing ultrashort peptides (including KED sequence) that normalize vascular endothelial function, reduce total cholesterol by up to 30% in clinical studies, and restore arterial elasticity through epigenetic regulation of extracellular matrix remodeling genes in aging blood vessels

  • Anti-Aging
  • Anti-Aging

At a glance

Quick comparison

Dose rangeCartalax200–200 mcgVentfort2–2 capsules
FrequencyCartalaxOnce dailyVentfortOnce daily
AdministrationCartalaxOral (capsule)VentfortSublingual (enteric-coated capsules)
Cycle lengthCartalax12+ weeksVentfort12+ weeks
Onset speedCartalaxGradual (3-4 weeks)VentfortGradual (3-4 weeks)
Evidence levelCartalaxModerate human trials (Phase 1-2)VentfortLimited human trials

Efficacy

Benefit ratings

Anti-Aging

Cartalax8%
VentfortNo recorded rating

Healing & Recovery

Cartalax8%
VentfortNo recorded rating

Hormone Support

Cartalax6%
VentfortNo recorded rating

Blood Vessel Health

CartalaxNo recorded rating
Ventfort94%

Cholesterol Support

CartalaxNo recorded rating
Ventfort88%

Heart Protection

CartalaxNo recorded rating
Ventfort85%

Technical data

Compound specifications

Cartalax

Molecular formula
C12H19N3O8
Molecular weight
333.3 g/mol
Half-life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids
Bioavailability
Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)
CAS number
Not yet registered (research compound)

Ventfort

Molecular formula
Complex peptide mixture (multiple sequences, MW range up to 5 kDa; active component KED: C13H22N4O7)
Molecular weight
Complex mixture up to 5,000 Da; KED active tripeptide: ~362.3 g/mol
Half-life
Short plasma half-life typical of ultrashort peptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to vascular gene expression; metabolized to constituent amino acids
Bioavailability
Oral formulation absorbed via intestinal peptide transporters; ultrashort peptides in the complex have efficient cellular uptake; injectable form provides direct systemic delivery; tissue-derived peptides maintain bioactivity through enteric-coated capsule formulation
CAS number
Not applicable (tissue-derived complex)

Protocols

Dosing compared

Cartalax

Subcutaneous

  • 200 mcgOnce daily · 10-day cycles, repeated periodicallyCartalax has only lab and cell-culture research, so there is no trial-set human dose. In practice it is commonly given as 200 mcg daily in short 10-day cycles, matching how other Khavinson short peptides are used [3][4].

Ventfort

Oral administration

  • 1 capsule (10 mg) once dailyOnce daily before meals · 10-day initial courseKhavinson A-3 vascular bioregulator (Ventfort); each capsule contains 10 mg peptide complex from vascular tissue [6]. Dietary-supplement form; research/wellness use.
  • 2 capsules (20 mg) dailyOnce or twice daily before meals · 10–20 day courseStandard daily dose (20 mg/day); courses typically repeated every 6 months [6]. Sublingual enteric-coated capsules used for buccal absorption.

Subcutaneous injection

  • 5–10 mgOnce daily · 10–20 day courseInjectable form of the A-3 complex for direct systemic delivery; same course length as oral [6]. Research use only.

Applications

Best suited for

Cartalax

Cartilage regeneration and protection in age-related osteoarthritis
Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Connective tissue repair and maintenance in aging individuals
Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Ventfort

Cardiovascular geroprotection — preserving vascular function during aging
Ventfort is particularly well-suited for individuals focused on cardiovascular geroprotection — preserving vascular function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Age-related arterial stiffness and endothelial dysfunction
Ventfort is particularly well-suited for individuals focused on age-related arterial stiffness and endothelial dysfunction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Lipid profile optimization as adjunctive support alongside lifestyle modifications
Ventfort is particularly well-suited for individuals focused on lipid profile optimization as adjunctive support alongside lifestyle modifications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting cardiovascular health
Ventfort is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting cardiovascular health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Cartalax

Common

  • Mild injection site reaction
  • Mild GI discomfort
  • Mild fatigue
  • Transient joint stiffness

Uncommon

  • Temporary increase in joint discomfort

Serious

  • No documented serious adverse effects

Ventfort

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Mild blood pressure fluctuation

Uncommon

  • Mild dizziness

Serious

  • No documented serious adverse effects

Research status

Safety & evidence

Cartalax

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active joint infection — treat infection before initiating peptide bioregulator therapy
  • Malignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated

Ventfort

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Ventfort (collagen peptide complex) demonstrates excellent safety profile from cosmetic and nutritional supplement use spanning decades. Hydrolyzed collagen peptides pass through the GI tract largely unchanged—minimal systemic absorption occurs, making serious adverse effects unlikely. Mild gastrointestinal side effects (bloating, dyspepsia) occur in <5% of users and are generally self-limiting. Allergic reactions are rare given the high molecular weight peptide fragments; histamine content is negligible in properly processed formulations.

Contraindications

  • Known hypersensitivity to bovine-derived peptide products or any constituent amino acids
  • Active bleeding disorders or concurrent anticoagulant therapy without medical supervision
  • Severe cardiovascular disease requiring immediate medical intervention
  • Pregnancy and breastfeeding — insufficient reproductive safety data

Decision guide

Which is right for you?

Cartalax

Choose Cartalax if…

  • Cartilage regeneration and protection in age-related osteoarthritis
  • Connective tissue repair and maintenance in aging individuals
  • Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
  • Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy

Ventfort

Choose Ventfort if…

  • Cardiovascular geroprotection — preserving vascular function during aging
  • Age-related arterial stiffness and endothelial dysfunction
  • Lipid profile optimization as adjunctive support alongside lifestyle modifications
  • Comprehensive Khavinson bioregulator protocols targeting cardiovascular health